Author

C. Roemer-Bécuwe

Observed names: C Becuwe, C Roemer-Becuwe, C. Becuwe, C. Roemer-Becuwe, Celia Roemer Becuwe, Celia Roemer-Becuwe, Célia Becuwe, Célia Becuwe-Roemer, Célia Roemer-Becuwe, Célia Roemer-Bécuwe, ROEMER-BECUWE, Célia, Roemer-Becuwe, Célia

Observed institutions: The University of Texas MD Anderson Cancer Center, Grey Nuns Community Hospital, Centre Hospitalier Universitaire de Besançon, Centre Georges François Leclerc, Institut de Cancérologie de Lorraine, Centre Léon Bérard, Centre Eugène Marquis, Centre François Baclesse, Centre Oscar Lambret, Institut Bergonié, Institut Jean Godinot, Centre Henri Becquerel, Institut Regional du Cancer de Montpellier, Université Henri Poincaré

OpenAlex ID: A5042166901

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

2020 · Jacobus Pfisterer, Catherine M Shannon, et al. · The Lancet Oncology · 167

PDF

Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial

2023 · Jean-Emmanuel Kurtz, Eric Pujade-Lauraine, et al. · Journal of Clinical Oncology · 113

Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO

2013 · I Ray-Coquard, L Favier, et al. · British Journal of Cancer · 106

PDF

Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial

2009 · J.E. Kurtz, A.-C. Hardy-Bessard, et al. · Gynecologic Oncology · 87

Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach

2017 · Michele Boisdron-Celle, Olivier Capitain, et al. · Seminars in Oncology · 80

Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I–type II study from the GINECO group

2017 · P-E Heudel, M Fabbro, et al. · British Journal of Cancer · 68

PDF

When Midazolam Fails

2002 · Christine Cheng, Célia Roemer-Becuwe, et al. · Journal of Pain and Symptom Management · 66

PDF

Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study

2019 · F. Joly, D. Ahmed-Lecheheb, et al. · Annals of Oncology · 57

A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer

2016 · Giuseppe Curigliano, Gilles Romieu, et al. · Breast Cancer Research and Treatment · 45

Safety of subcutaneous clodronate and efficacy in hypercalcemia of malignancy: a novel route of administration

2003 · Célia Roemer-Bécuwe, Antonio Vigano, et al. · Journal of Pain and Symptom Management · 28

PDF

A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study

2016 · O. Trédan, P. Follana, et al. · Annals of Oncology · 27

PDF

Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial

2016 · Roberto Sorio, Célia Roemer-Becuwe, et al. · Gynecologic Oncology · 26

Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY

2023 · Judith Balmaña, Peter A. Fasching, et al. · Breast Cancer Research and Treatment · 25

Analysis of the StoRM cohort reveals physical activity to be associated with survival in metastatic breast cancer

2020 · Lidia Delrieu, Emmanuelle Jacquet, et al. · Scientific Reports · 22

PDF

Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy – The GCIG symptom benefit study (SBS)

2019 · F.T. Roncolato, R.L. O'Connell, et al. · Gynecologic Oncology · 10

PDF

Guide de recommandations d’utilisation des bisphosphonates dans les lésions osseuses malignes des tumeurs solides et du myélome multiple

2011 · J.-F. Brantus, C. Roemer-Becuwe, et al. · La Revue de Médecine Interne · 10

Phase II study of the PI3K inhibitor BKM120 monotherapy in patients with advanced or recurrent endometrial carcinoma: ENDOPIK, GINECO Study.

2015 · Pierre-Etienne Heudel, Michel Fabbro, et al. · Journal of Clinical Oncology · 9

[Bisphosphonates, pain and quality of life in metastatic breast cancer patients: a literature review].

2003 · Célia Roemer-Becuwe, Ivan Krakowski, et al. · PubMed · 9

Prevention of 5-FU-induced health-threatening toxicity by pretherapeutic DPD deficiency screening: Medical and economic assessment of a multiparametric approach.

2013 · Michele Boisdron-Celle, Olivier Capitain, et al. · Journal of Clinical Oncology · 7

2095 Survival benefit, safety, and prognostic factors for outcome with Regorafenib (RE) in patients (pts) with pretreated metastatic colorectal cancer (mCRC). Main analyses of the REBECCA study

2015 · C. De La Fouchardiere Fontaniere, B. Paule, et al. · European Journal of Cancer · 3

Prevention of 5-FU-induced toxicities using pretherapeutic DPD deficiency screening: Medical and economic assessment of a multiparametric approach.

2013 · Michele Boisdron-Celle, Olivier Capitain, et al. · Journal of Clinical Oncology · 3

Cetuximab (Ce) + topotecan (Tc) + cisplatin (Cp) for the treatment (Tt) of advanced cervix cancer (ACC): A phase II GINECO trial

2008 · E. Kurtz, D. Besson, et al. · Journal of Clinical Oncology · 3

Final Results From the ATALANTE/ENGOT-ov29 Randomized Phase III Trial of Atezolizumab, Bevacizumab, and Platinum-Based Therapy for Late-Relapsing Recurrent Ovarian Cancer

2026 · Jean-Emmanuel Kurtz, Eric Pujade-Lauraine, et al. · JCO oncology advances. · 1

Outcomes of the combination trabectedin and pegylated liposomal doxorubicin (T-PLD) in recurrent platinum-sensitive ovarian cancer (OC): a GINECO cohort study

2017 · F. Selle, P-E. Heudel, et al. · Annals of Oncology · 1

PDF

Predictors of stopping chemotherapy early and short survival in patients with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) who have had ≥3 lines of prior chemotherapy: The GCIG symptom benefit study (SBS).

2017 · Felicia Roncolato, Florence Joly, et al. · Journal of Clinical Oncology · 1

Works count: 42

Citation count: 977

H-index: 14

I10-index: 16